Precision BioSciences DMD Data Bolsters Gene Editing Approach Ahead of Trial

Event summary

  • Precision BioSciences presented preclinical data for PBGENE-DMD at the Muscular Dystrophy Association Clinical & Scientific Conference 2026.
  • The data, from a humanized DMD mouse model, showed improvements in muscle damage markers, including a ~50-65% reduction in CK levels at 90 days post-treatment.
  • PBGENE-DMD aims to treat up to 60% of DMD patients with mutations in exons 45-55 by restoring dystrophin production.
  • The Phase 1/2 FUNCTION-DMD clinical trial is expected to enroll patients aged 2-7 and begin in the first half of 2026.

The big picture

Precision BioSciences' PBGENE-DMD represents a differentiated approach to treating Duchenne muscular dystrophy, moving beyond microdystrophin and exon skipping therapies. The company’s reliance on its ARCUS platform positions it within a rapidly evolving gene editing landscape, where durability and targeted delivery remain critical challenges. Success with PBGENE-DMD could validate Precision BioSciences’ in vivo gene editing strategy and potentially open doors for similar therapies targeting other genetic diseases.

What we're watching

Clinical Translation
The success of the FUNCTION-DMD trial will hinge on whether preclinical improvements translate to meaningful patient outcomes, particularly given the complexity of DMD.
Satellite Cell Editing
The long-term durability of PBGENE-DMD’s effect will depend on the continued activity of edited muscle satellite cells, which requires ongoing monitoring.
Regulatory Pathway
Given the novelty of the gene editing approach, the FDA’s ongoing assessment of safety and efficacy will be a key determinant of future development and commercialization.

Related topics

Clinical Trial